Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

Stealth BioTherapeutics Corp

A clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction.

Stealth BioTherapeutics

Careers at Stealth BioTherapeutics

Our Mission
Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Our team works with patients and advocacy organizations to better understand their journey and raise awareness of the unmet need our programs seek to address.

We collaborate with top-tier academic and medical institutions, scientific thought leaders, and clinical key opinion leaders in developing the first generation of targeted therapies focusing on mitochondrial dysfunction as it presents in these rare genetic diseases and common diseases of aging. With these collaborative efforts, we continue to advance our platform of late-stage clinical programs and novel pipeline candidates.

Please be aware of the potential for scams claiming to represent Stealth BioTherapeutics in recruitment activities. Stealth exclusively uses @stealthbt.com e-mail addresses for recruitment purposes and does not conduct interviews via social media or other third-party sites. Please report any suspicious recruiting activity to us at careers@stealthbt.com and to the Internet Crime Complaint Center.

Sagamore Investments

Ocean Equity Partners

Pivotal bioVenture Partners

Atlantis Investment Management

BVCF

CMBC Capital Holdings

Kingdon Capital

Horizon Technology Finance

Morningside Venture Investments

Last month, we had the privilege of discussing varied pathways for patient-inspired drug development at #BIO2024. Our CEO, Reenie McCarthy, shared about our long-standing and ongoing focus on patient-directed drug development and spoke alongside I. Sika D. of Travere Therapeutics, Danae'​ Bartke of HCU Network America, Jessica Tome Garcia, Ph.D. of The Michael J. Fox Foundation for Parkinson's Research, and Stacey Frisk of The Rare Disease Company Coalition. 
 
In the eight years since the passage of the 21st Century Cures Act, patient involvement in drug development has exploded. Millions of families affected by serious conditions, particularly in #RareDisease, now have time-tested paths to follow in their pursuit of a life-changing treatment. But patient-focused drug development meetings (PFDDs) are only part of the story. In fact, different paths in drug development have emerged as varied as the challenges that patients themselves face every day. This session explored different roads taken by stakeholders to drive patient input into drug development, inspiring hope for those interested in progress toward novel therapies. #not2rare2care

We had a wonderful time connecting with others in the #MitochondrialDisease community at the United Mitochondrial Disease Foundation #MitoMed conference last week! Our CEO, Reenie McCarthy, presented an update on our clinical programs, emphasizing key learnings, the importance of perseverance, and the value of first approvals that can inform further research and advancements. We’re already looking forward to next year’s conference!

Thank you to the United Mitochondrial Disease Foundation for hosting a wonderful #MitoMed 2024 conference in Cleveland, OH! Thank you to everyone who stopped by our booth to learn more about our work in #mitochondrialdisease. It was a pleasure connecting with patients, families, advocates, researchers, clinicians, and members of the community. Until next year!

Join us at tomorrow’s virtual #MitochondrialDisease Caucus Congressional briefing, “Transforming Patient Outcomes in Mitochondrial Disease: Raising Awareness, Enabling Innovation, Driving Change.” Our CEO Reenie McCarthy will join Emily Milligan of the Barth Syndrome Foundation, Kira Mann of MitoAction, Dr. Hilary Vernon of the The Johns Hopkins University School of Medicine, and Andrew Dearth of the United Mitochondrial Disease Foundation to discuss the need for continued innovation in #MitochondrialMedicine across the patient journey – from diagnosis to drug development – and opportunities to chart a path forward. 
Register here: https://lnkd.in/ewkCbRZ3

#ICYMI: You can tune into the live replay of the recent EveryLife Foundation for Rare Diseases scientific workshop focused on the challenges and opportunities in developing much-needed therapies for ultra-rare diseases. Our CEO, Reenie McCarthy starts speaking at 1:48:40. #not2rare2care https://lnkd.in/dxJF89b

#MitoMed2024 is right around the corner and the Stealth team is excited to be in Cleveland sharing more about our work from our program in primary mitochondrial myopathy and our expanded access program. You can find all the conference details at https://umdfconference.org

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21
average inventory
average payables		5.18M -	9.24M 78.29%	10.27M 11.18%	6.52M 36.49%	3.50M 46.40%
average receivables
book value per share	-10.29 -	-18.34 78.15%	-11.71 36.13%	0.55 104.71%	-0.22 140.57%	-0.98 336.70%
capex per share	-0.01 -	-0.01 28.25%	-0.00 96.52%	-0.00 1,076.72%	-0.00 81.81%	-0.00 91.43%
capex to depreciation	-0.92 -	-0.46 49.63%	-0.04 91.87%	-0.46 1,114.06%	-0.15 67.04%	-0.87 476.77%
capex to operating cash flow	0.01 -	0.00 56.75%	0.00 92.99%	0.00 1,575.91%	0.00 75.87%	0.00 127.90%
capex to revenue				-0.01 -
cash per share	0.48 -	0.26 45.56%	0.33 26.79%	1.62 393.27%	0.71 56.38%	1.02 43.76%
days of inventory on hand
days payables outstanding
days sales outstanding
debt to assets	16.75 -	41.71 149.02%	25.91 37.88%	0.67 97.40%	1.29 91.69%	1.90 47.50%
debt to equity	-1.06 -	-1.02 3.66%	-1.04 1.52%	2.05 297.53%	-4.46 316.90%	-2.11 52.68%
dividend yield
earnings yield	-0.25 -	-0.44 74.28%	-0.25 43.88%	-0.70 185.54%	-0.83 17.99%	-1.37 64.67%
enterprise value	232.86M -	248.95M 6.91%	504.10M 102.49%	67.53M 86.60%	45.50M 32.62%	4.99M 89.03%
enterprise value over ebitda	-3.83 -	-3.14 18.10%	-6.72 113.91%	-1.04 84.48%	-0.82 21.24%	-0.10 88.13%
ev to operating cash flow	-4.31 -	-3.56 17.30%	-6.99 96.19%	-1.41 79.88%	-0.85 39.61%	-0.11 86.95%
ev to sales				3.20 -
free cash flow per share	-2.66 -	-4.41 65.40%	-2.18 50.45%	-1.54 29.61%	-1.16 24.79%	-0.97 15.93%
free cash flow yield	-0.22 -	-0.37 65.40%	-0.18 50.45%	-0.47 156.96%	-0.77 64.01%	-1.17 51.42%
graham net net	-10.47 -	-18.53 76.96%	-11.85 36.03%	0.49 104.12%	-0.29 159.33%	-1.04 260.20%
graham number	26.34 -	46.41 76.20%	27.78 40.13%	5.33 80.81%	2.50 53.15%	4.99 99.81%
income quality	0.88 -	0.84 4.81%	0.75 11.52%	0.67 10.24%	0.93 39.29%	0.86 8.12%
intangibles to total assets	0 -	0	0	0	0	0
interest coverage		-24.29 -	-3.52 85.49%	-6.88 95.06%	-26.92 291.53%	-37.28 38.49%
interest debt per share		4.11 -	4.34 5.74%	0.73 83.15%	0.04 94.67%	0.32 724.00%
inventory turnover
invested capital		-0.21 -	-0.32 48.37%	0.94 398.06%		-0.30 -
market cap	242.57M -	189.02M 22.08%	392.92M 107.87%	102.06M 74.03%	69.29M 32.11%	38.47M 44.48%
net current asset value	-211.71M -	-292.52M 38.17%	-388.94M 32.96%	16.92M 104.35%	-11.18M 166.07%	-45.92M 310.72%
net debt to ebitda	0.16 -	-0.76 572.86%	-1.48 95.98%	0.53 135.98%	0.43 19.47%	0.65 52.31%
net income per share	-2.99 -	-5.22 74.28%	-2.93 43.88%	-2.29 21.78%	-1.24 45.89%	-1.13 8.58%
operating cash flow per share	-2.65 -	-4.40 65.90%	-2.18 50.35%	-1.53 29.79%	-1.16 24.63%	-0.97 16.00%
payables turnover
receivables turnover
research and ddevelopement to revenue				2.12 -
return on tangible assets	-4.58 -	-11.59 152.87%	-6.23 46.23%	-1.36 78.17%	-1.60 17.86%	-1.05 34.75%
revenue per share				0.67 -
roe	0.29 -	0.28 2.17%	0.25 12.14%	-4.15 1,761.01%	5.54 233.35%	1.16 79.07%
roic	6.87 -	9.34 35.98%	4.37 53.16%	0.79 82.03%	1.46 86.23%	0.97 33.42%
sales general and administrative to revenue				1.06 -
shareholders equity per share	-10.29 -	-18.34 78.15%	-11.71 36.13%	0.55 104.71%	-0.22 140.57%	-0.98 336.70%
stock based compensation to revenue				0.15 -
tangible asset value	-209.83M -	-291.29M 38.82%	-386.71M 32.76%	17.27M 104.47%	-10.37M 160.07%	-45.30M 336.70%
tangible book value per share	-10.29 -	-18.34 78.15%	-11.71 36.13%	0.55 104.71%	-0.22 140.57%	-0.98 336.70%
working capital	-337.85K -	-18.67M 5,427.41%	-27.32M 46.28%	18.45M 167.53%	13.99M 24.16%	38.77M 177.14%

COM:STEALTHBT

Stealth BioTherapeutics

Last Close

0.32

15/11 21:00

Volume Today

1.30M

Avg: -

Preview